within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB12_AlbinterferonAlfa2b;

model AlbinterferonAlfa2b
  extends Pharmacolibrary.Drugs.ATC.L.L03AB12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L03AB12</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Albinterferon alfa-2b is a recombinant fusion protein of human albumin and interferon alfa-2b developed as a long-acting form of interferon for the treatment of chronic hepatitis C infection. It was intended to offer less frequent dosing schedules compared to traditional pegylated interferons, but its development was discontinued and it is not approved or in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for healthy adult subjects and patients with chronic hepatitis C, reported after subcutaneous administration.</p><h4>References</h4><ol><li><p>Rustgi, VK (2009). Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. <i>Current medical research and opinion</i> 25(4) 991–1002. DOI:<a href=\"https://doi.org/10.1185/03007990902779186\">10.1185/03007990902779186</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19275518/\">https://pubmed.ncbi.nlm.nih.gov/19275518</a></p></li><li><p>Riggs, MM, et al., &amp; Stein, DS (2012). Population pharmacokinetics and exposure-response of albinterferon alfa-2b. <i>Journal of clinical pharmacology</i> 52(4) 475–486. DOI:<a href=\"https://doi.org/10.1177/0091270011399576\">10.1177/0091270011399576</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21551316/\">https://pubmed.ncbi.nlm.nih.gov/21551316</a></p></li><li><p>Serra, DB, et al., &amp; Stein, DS (2011). Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. <i>Antimicrobial agents and chemotherapy</i> 55(2) 473–477. DOI:<a href=\"https://doi.org/10.1128/AAC.00626-10\">10.1128/AAC.00626-10</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21098255/\">https://pubmed.ncbi.nlm.nih.gov/21098255</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AlbinterferonAlfa2b;
